Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Persaud, P. Palumbo, C. Ziemniak, M. Hughes, C. Alvero, K. Luzuriaga, R. Yogev, E. Capparelli, E. Chadwick (2012)
Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of ageAIDS, 26
D. Persaud, S. Ray, Joleen Kajdas, A. Ahonkhai, G. Siberry, K. Ferguson, C. Ziemniak, T. Quinn, J. Casazza, S. Zeichner, S. Gange, D. Watson (2007)
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.AIDS research and human retroviruses, 23 3
Susanne Eriksson, E. Graf, V. Dahl, M. Strain, S. Yukl, E. Lysenko, R. Bosch, J. Lai, S. Chioma, Fatemeh Emad, M. Abdel-Mohsen, R. Hoh, F. Hecht, P. Hunt, M. Somsouk, J. Wong, Rowena Johnston, R. Siliciano, D. Richman, U. O’Doherty, S. Palmer, S. Deeks, J. Siliciano (2013)
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication StudiesPLoS Pathogens, 9
K. Luzuriaga, Hulin Wu, M. McManus, P. Britto, W. Borkowsky, S. Burchett, Betsy Smith, L. Mofenson, J. Sullivan (1999)
Dynamics of Human Immunodeficiency Virus Type 1 Replication in Vertically Infected InfantsJournal of Virology, 73
T. Le, J. Farrar, C. Shikuma (2011)
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.AIDS, 25 6
N. Archin, N. Vaidya, J. Kuruc, A. Liberty, A. Wiegand, Mary Kearney, M. Cohen, J. Coffin, R. Bosch, C. Gay, J. Eron, D. Margolis, A. Perelson (2012)
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infectionProceedings of the National Academy of Sciences, 109
S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G. Hanna, S. Brun, D. Kempf, J. Mellors, J. Coffin, M. King (2008)
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 105
K. Luzuriaga, M. McManus, M. Catalina, Shane Mayack, M. Sharkey, M. Stevenson, J. Sullivan (2000)
Early Therapy of Vertical Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Control of Viral Replication and Absence of Persistent HIV-1-Specific Immune ResponsesJournal of Virology, 74
J. Blankson, D. Finzi, T. Pierson, B. Sabundayo, K. Chadwick, J. Margolick, T. Quinn, T. Quinn, R. Siliciano (2000)
Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection.The Journal of infectious diseases, 182 6
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection — recommendations for a public health approach
K. Luzuriaga, M. McManus, L. Mofenson, P. Britto, B. Graham, J. Sullivan (2004)
A trial of three antiretroviral regimens in HIV-1-infected children.The New England journal of medicine, 350 24
M. Newell, H. Coovadia, M. Cortina-Borja, N. Rollins, P. Gaillard, F. Dabis (2004)
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysisThe Lancet, 364
K. Luzuriaga, Y. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, S. Cort, J. Sullivan (1997)
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.The New England journal of medicine, 336 19
M. Strain, S. Lada, T. Luong, S. Rought, S. Gianella, V. Terry, C. Spina, C. Woelk, D. Richman (2013)
Highly Precise Measurement of HIV DNA by Droplet Digital PCRPLoS ONE, 8
(2013)
Challenges and strategies towards functional cure: how low do you need to go
A. Violari, M. Cotton, D. Gibb, A. Babiker, Jan Steyn, S. Madhi, P. Jean‐Philippe, J. McIntyre (2008)
Early antiretroviral therapy and mortality among HIV-infected infants.The New England journal of medicine, 359 21
M. Buzón, Hong Sun, Chun Li, A. Shaw, Katherine Seiss, Zhengyu Ouyang, E. Martín-Gayo, J. Leng, T. Henrich, Jonathan Li, F. Pereyra, R. Zurakowski, B. Walker, E. Rosenberg, Xu Yu, M. Lichterfeld (2014)
HIV-1 persistence in CD4+ T cells with stem cell-like propertiesNature medicine, 20
Ellen Chadwick, J. Rodman, P. Britto, C. Powell, P. Palumbo, K. Luzuriaga, M. Hughes, E. Abrams, P. Flynn, W. Borkowsky, R. Yogev (2005)
Ritonavir-Based Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Infants Younger Than 24 Months of AgeThe Pediatric Infectious Disease Journal, 24
D. Persaud, H. Gay, C. Ziemniak, Y. Chen, M. Piatak, T. Chun, M. Strain, D. Richman, K. Luzuriaga (2013)
Absence of detectable HIV-1 viremia after treatment cessation in an infant.The New England journal of medicine, 369 19
B. Julg, F. Pereyra, M. Buzón, A. Piechocka-Trocha, A. Piechocka-Trocha, M. Clark, Brett Baker, J. Lian, T. Miura, T. Miura, T. Miura, Javier Martínez-Picado, M. Addo, Bruce Walker, Bruce Walker (2010)
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51 2
M. Zanchetta, Sarah Walker, N. Burighel, D. Bellanova, O. Rampon, C. Giaquinto, A. Rossi (2006)
Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy.The Journal of infectious diseases, 193 12
M. Strain, S. Little, E. Daar, D. Havlir, H. Gunthard, R. Lam, O. Daly, Juin Nguyen, C. Ignacio, C. Spina, D. Richman, J. Wong (2005)
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.The Journal of infectious diseases, 191 9
T. Chun, D. Murray, J. Justement, C. Hallahan, S. Moir, C. Kovacs, A. Fauci (2011)
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.The Journal of infectious diseases, 204 1
B. Richardson, D. Mbori-ngacha, L. Lavreys, G. John-Stewart, R. Nduati, D. Panteleeff, S. Emery, J. Kreiss, J. Overbaugh (2003)
Comparison of Human Immunodeficiency Virus Type 1 Viral Loads in Kenyan Women, Men, and Infants during Primary and Early InfectionJournal of Virology, 77
T. Greenough, C. Cunningham, Petronella Muresan, M. McManus, D. Persaud, T. Fenton, P. Barker, A. Gaur, D. Panicali, J. Sullivan, K. Luzuriaga (2008)
Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.Vaccine, 26 52
J. Oleske, G. Scott (1998)
Guidelines for the use of antiretroviral agents in pediatric HIV infection
W. Shearer, T. Quinn, P. LaRussa, J. Lew, L. Mofenson, S. Almy, K. Rich, E. Handelsman, Clemente Díaz, M. Pagano, V. Smeriglio, L. Kalish (1997)
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.The New England journal of medicine, 336 19
J. Giorgi, R. Detels (1989)
T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study.Clinical immunology and immunopathology, 52 1
W. Shearer, H. Rosenblatt, R. Gelman, R. Oyomopito, S. Plaeger, E. Stiehm, D. Wara, S. Douglas, K. Luzuriaga, E. McFarland, R. Yogev, Mobeen Rathore, W. Levy, B. Graham, S. Spector (2003)
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.The Journal of allergy and clinical immunology, 112 5
N. Chomont, M. El-Far, P. Ancuța, L. Trautmann, F. Procopio, B. Yassine-Diab, G. Boucher, M. Boulassel, G. Ghattas, J. Brenchley, T. Schacker, Brenna Hill, D. Douek, J. Routy, E. Haddad, R. Sékaly (2009)
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 15
D. Finzi, J. Blankson, J. Siliciano, J. Margolick, K. Chadwick, T. Pierson, Kendall Smith, J. Lisziewicz, F. Lori, C. Flexner, T. Quinn, R. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, R. Siliciano (1999)
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyNature Medicine, 5
B. Emu, E. Sinclair, H. Hatano, A. Ferre, B. Shacklett, Jeffrey Martin, J. McCune, S. Deeks (2008)
HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus ControlJournal of Virology, 82
L. Hocqueloux, V. Avettand-Fenoël, Sophie Jacquot, T. Prazuck, E. Legac, A. Mélard, M. Niang, C. Mille, G. Moal, J. Viard, C. Rouzioux (2013)
Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.The Journal of antimicrobial chemotherapy, 68 5
J. Ananworanich, A. Schuetz, C. Vandergeeten, I. Sereti, M. Souza, R. Rerknimitr, R. Dewar, M. Marovich, F. Griensven, R. Sékaly, S. Pinyakorn, N. Phanuphak, R. Trichavaroj, Wiriya Rutvisuttinunt, N. Chomchey, R. Paris, S. Peel, V. Valcour, F. Maldarelli, N. Chomont, N. Michael, P. Phanuphak, Jerome Kim (2012)
Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV InfectionPLoS ONE, 7
A. Sáez-Cirión, C. Bacchus, L. Hocqueloux, V. Avettand-Fenoel, I. Girault, C. Lécuroux, V. Potard, P. Versmisse, A. Mélard, T. Prazuck, B. Descours, J. Guergnon, J. Viard, F. Boufassa, O. Lambotte, C. Goujard, L. Meyer, D. Costagliola, A. Venet, G. Pancino, B. Autran, C. Rouzioux (2013)
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI StudyPLoS Pathogens, 9
Background. Early initiation of combination antiretroviral therapy (cART) to human immunodeficiency virus type 1 (HIV-1)–infected infants controls HIV-1 replication and reduces mortality.Methods. Plasma viremia (lower limit of detection, <2 copies/mL), T-cell activation, HIV-1–specific immune responses, and the persistence of cells carrying replication-competent virus were quantified during long-term effective combination antiretroviral therapy (cART) in 4 perinatally HIV-1–infected youth who received treatment early (the ET group) and 4 who received treatment late (the LT group). Decay in peripheral blood mononuclear cell (PBMC) proviral DNA levels was also measured over time in the ET youth.Results. Plasma viremia was not detected in any ET youth but was detected in all LT youth (median, 8 copies/mL; P = .03). PBMC proviral load was significantly lower in ET youth (median, 7 copies per million PBMCs) than in LT youth (median, 181 copies; P = .03). Replication-competent virus was recovered from all LT youth but only 1 ET youth. Decay in proviral DNA was noted in all 4 ET youth in association with limited T-cell activation and with absent to minimal HIV-1–specific immune responses.Conclusions. Initiation of early effective cART during infancy significantly limits circulating levels of proviral and replication-competent HIV-1 and promotes continuous decay of viral reservoirs. Continued cART with reduction in HIV-1 reservoirs over time may facilitate HIV-1 eradication strategies.
Journal of Infectious Diseases – Oxford University Press
Published: Nov 15, 2014
Keywords: continuous HIV-1 decay; proviral reservoirs; early antiretroviral therapy; prolonged viral suppression; reduced HIV reservoirs
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.